Self-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy

Procedural Pain Clinical Trial

— SANO-VAS  

Official title:

Self-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05895383
• Other study ID #: 2023P-000328
• Status: Recruiting
• Phase: Phase 4
• Start date: May 24, 2023
• Est. completion date: November 30, 2023

Study information

• Verified date: June 2023
• Source: Beth Israel Deaconess Medical Center
• Contact: Heidi Rayala, MD, PhD
• Phone: 617-667-3739
• Email: hrayala[@]bidmc.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to see if nitrous oxide during vasectomy decreases pain and anxiety, and also assess whether patients have better satisfaction when they control their own level of nitrous oxide during the procedure. If we find that patients experience less pain or anxiety with nitrous oxide, it could be suggested that self-adjusted nitrous oxide (SANO) may be a useful tool for improving experience of care during vasectomy.

Description:

Patients scheduled for vasectomy at Beth Israel Deaconess Medical Center will be contacted and offered enrollment in the study. Vasectomy will occur according to standard-of-care and all participants will receive the typical lidocaine injections at the beginning of the procedure. Before the start of the vasectomy, a study staff member will help participants put on a plastic gas mask and demonstrate how to turn the gas up or down using the remote control. Nitrous oxide and oxygen will be given through a plastic mask. A remote control given to participants will allow them to adjust the nitrous oxide based on their comfort. The Nitrouseal® machine used in this study limits nitrous oxide to concentrations to "minimal sedation" (0-50%), which are levels where a person remains awake and is able to talk and breath normally.

Before the day of a participant's vasectomy, they will be asked questions related to demographics and medical history to determine study eligibility. Immediately before and after vasectomy, participants will be asked to describe their anxiety and pain levels. At two-weeks and three-months after vasectomy, a brief electronic survey will be sent to participants' email asking about recollection of pain and anxiety and satisfaction with the procedure.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 35
• Est. completion date: November 30, 2023
• Est. primary completion date: September 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 21 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Scheduled for vasectomy

2. Aged 21 to 85 years

3. Suitable for receipt of inhaled nitrous oxide/oxygen

4. Access to an email and computer

Exclusion Criteria:

1. Perioral facial hair impeding good mask seal

2. Cognitive impairment that impedes ability to complete survey questions

3. Intent to use benzodiazepines or opioids "as needed" for purposes of vasectomy

4. Has any of the following medical conditions, which contraindicate use of nitrous oxide:

1. Inner ear, bariatric or eye surgery within the last 2 weeks,

2. Current emphysematous blebs,

3. Severe B-12 deficiency,

4. Bleomycin chemotherapy within the past year,

5. Heart attack within the past year,

6. Stroke within the past year,

7. Class III or higher heart failure.

Related Conditions & MeSH terms

• Pain Catastrophizing
• Pain, Procedural
• Procedural Anxiety
• Procedural Pain

Intervention

Drug:
• Nitrous oxide
Nitrous oxide administered at concentrations of minimal sedation (0-50%). Participants will be able to adjust the level of gas throughout the vasectomy using a handheld remote control.

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Beth Israel Deaconess Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Procedural pain assessed by the Visual Analog Scale for Pain (VAS-P)	Level of pain experienced during vasectomy as measured by the Visual Analog Scale for Pain (VAS-P; range: 0 no pain - 10 worst pain).	Measured immediately after completion of vasectomy
Secondary	Anticipated pain assessed by the Visual Analog Scale for Pain (VAS-P)	Level of anxiety anticipated during vasectomy as measured by the Visual Analog Scale for Pain (VAS-P; range: 0 no pain - 10 worst pain).	Measured immediately prior to vasectomy
Secondary	Anticipated anxiety assessed by the Visual Analog Scale for Anxiety (VAS-A)	Level of anxiety anticipated during vasectomy as measured by the Visual Analog Scale for Anxiety (VAS-A; range: 0 no anxiety - 10 worst anxiety).	Measured immediately prior to vasectomy
Secondary	Procedural anxiety assessed by the Visual Analog Scale for Anxiety (VAS-A)	Level of anxiety experienced during vasectomy as measured by the Visual Analog Scale for Anxiety (VAS-A; range: 0 no anxiety - 10 worst anxiety).	Measured immediately after completion of vasectomy
Secondary	Recalled pain assessed by the Visual Analog Scale for Pain (VAS-P)	Level of pain recalled during vasectomy as measured by the Visual Analog Scale for Pain (VAS-P; range: 0 no pain - 10 worst pain).	Measured two weeks and three months after vasectomy
Secondary	Recalled anxiety assessed by the Visual Analog Scale for Pain (VAS-P)	Level of anxiety recalled during vasectomy as measured by the Visual Analog Scale for Anxiety (VAS-A; range: 0 no anxiety - 10 worst anxiety).	Measured two weeks and three months after vasectomy
Secondary	Satisfaction assessed by Likert scale	Satisfaction of concentration of SANO during vasectomy will be measured by the maximum concentration of SANO reached during the procedure compared to participants' response to: "How do you feel about the level of SANO you received during the vasectomy?" (less than I would like, about right, more than I would like) and "How helpful do you think SANO was in relieving your pain and anxiety?" (very helpful, unhelpful, undecided, helpful very helpful).	Measured during and two weeks after vasectomy
Secondary	Operator ease of performing vasectomy	Operating urologist will be asked to fill out a three-item "operator survey" that asks if "Patient tolerated lidocaine injection," "Patient maintained positioning," and "Patient tolerated vasectomy," "Worse than expected (-1)", "As expected (0)" or "Better than expected (+1)." The composite score will be used as a measure of operator ease.	Measured immediately after urologist finishes vasectomy
Secondary	Emergent adverse events as assessed by frequency of incidents	Emergent adverse events possibly related to SANO will be recorded by frequency on the day-of the vasectomy and by monitoring participants' online medical record up to 30 days after the vasectomy. Termination of SANO during the vasectomy due to discomfort, nausea, or vomiting will also be considered as adverse events related to SANO.	Measured during and up to 30 days after day of vasectomy